> 
Paris, 21 january 2013
Lupus : peptide P140/LupuzorTM effectiveness confirmed
A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France. The peptide, known as P140/LupuzorTM, is well tolerated by patients and leads to regression of the disease. Under the CNRS patent, ImmuPharma-France, which funded the trial, has an exclusive license to use the peptide. Now the final phase of clinical tests should soon confirm these results and contribute to the development of a drug without the side effects of existing treatments, which use cortico-steroids and immunosuppressants. These results are published online in the Annals of the Rheumatic Diseases.
To download the press release 
References:
Zimmer R., Scherbarth H.R., Rillo O.L., Gomez-Reino J. and Muller S. Annals of Rheumatic Diseases (doi: 10.1136/annrheumdis-2012-202460)
Contact information:
CNRS Researcher l Sylviane Muller l T +33 3 88 41 70 22 l S.Muller@ibmc-cnrs.unistra.fr
ImmuPharma l Robert Zimmer l T +33 3 89 66 13 22 l robert.zimmer@immupharma.com
CNRS Press l Laetitia Louis l T +33 1 44 96 51 37 l laetitia.louis@cnrs-dir.fr
Latest press releases
All disciplines
- 16 may 2013
Resistance to visceral leishmaniasis : new mechanisms involved - 15 may 2013
Discovery of a molecule derived from cholesterol that has anti-cancer properties - 6 may 2013
Chikungunya : discovery of a human-specific factor involved in the virus replication - 29 april 2013
Brilliant dye to probe the brain - 26 april 2013
Let's twist again : the role of cellulose in stem twisting - 25 april 2013
The Earth's Centre is 1000 Degrees Hotter than Previously Thought - 25 april 2013
Musical memory deficits start in auditory cortex - 23 april 2013
Tara Oceans Polar Circle : a new scientific expedition in the Arctic
